Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Active, not recruiting · NCT04762979 · Registry updated 2026-01-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | HER2-negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; PIK3CA Mutant Metastatic Breast Cancer | Active, not recruiting | Phase 2 | 2026-01-02 | NCT04762979 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Marina N Sharifi | 1 |
| Novartis | 114 |
| University of Wisconsin, Madison | 265 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Penn State Cancer Institute | Hershey | United States | 17 |
| University of Illinois Cancer Center | Chicago | United States | 34 |
| University of Nebraska Medical Center | Omaha | United States | 397 |
| University of Wisconsin | Madison | United States | 64 |